Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Annual General Meeting

Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.

Torrent Pharmaceuticals Other Announcement

Torrent Pharmaceuticals Limited has been assigned an ESG rating of 70 by NSE Sustainability Ratings and Analytics Limited. This independent assessment follows SEBI's regulatory framework for ESG Rating Providers.

Torrent Pharmaceuticals Annual General Meeting

Torrent Pharmaceuticals issued a Postal Ballot notice to shareholders for the appointment of Shanti Ekambaram as an Independent Director. Voting concludes on September 6, 2026.

Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways

Torrent Pharma delivered strong Q1 performance with revenues up 55% following the JB Chemicals merger completion. EBITDA margins jumped to 33.8% driven by accelerated cost synergies.

Call

Guides 10% growth

Torrent Pharmaceuticals Other Announcement

Torrent Pharmaceuticals submitted a statement under Regulation 52(7) & (7A) regarding the utilization of issue proceeds for the quarter ended June 30, 2026.

Torrent Pharmaceuticals Q1 FY27 Results: Net Profit ₹566 Cr, Up 3.3% YoY

Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,921 Cr (+54.8% YoY) and net profit of ₹566 Cr (+3.3% YoY) for Q1 FY27.

Key figure

Net profit ₹566 Cr · +3.3% YoY

Torrent Pharmaceuticals Management Change

Torrent Pharmaceuticals appointed Shanti Ekambaram as an Additional Independent Director. The appointment is for a three-year term effective July 30, 2026.

Torrent Pharmaceuticals Merger & Restructuring

Torrent Pharmaceuticals allotted 4,19,22,416 equity shares to J.B. Chemicals shareholders. This allocation follows a Scheme of Amalgamation sanctioned by the NCLT.

Torrent Pharmaceuticals Merger & Restructuring Worth ₹1.3 Cr

Torrent Pharmaceuticals announced the voluntary dissolution of its Philippines-based subsidiary, Curatio Inc. The entity contributed Rs 1.3 Crore to the consolidated net worth.

Value

₹1.30 Cr

Torrent Pharmaceuticals Other Announcement

Torrent Pharmaceuticals received an ESG rating of 66 and a Core ESG rating of 74 from Crisil. These ratings assess the company's environmental, social, and governance performance.

Torrent Pharmaceuticals Board Meeting Date

Torrent Pharmaceuticals will hold a Board Meeting on July 30, 2026. The meeting will consider financial results for the quarter ended June 30, 2026.

Torrent Pharmaceuticals Adverse Business Impact

Torrent Pharmaceuticals initiated a voluntary recall for select batches of Semalix Injection Disposable Pens. The precautionary action follows a technical evaluation recall by manufacturer Dr. Reddy's.

Torrent Pharmaceuticals Merger & Restructuring

Torrent Pharma announced NCLT's final order sanctioning its amalgamation with J.B. Chemicals. The scheme will become effective after filing with the Registrar of Companies.

Torrent Pharmaceuticals Debt & Borrowing

Torrent Pharmaceuticals filed a security cover certificate for its non-convertible debentures. The certificate confirms a standalone security cover of 0.33 times book value.

Torrent Pharmaceuticals Debt & Borrowing: ₹16,374 Cr

Torrent Pharmaceuticals is valuing key brands at Rs. 16,374.09 Crore to raise funds via NCDs. The valuation includes brands like Nexpro, Chymoral, Rozucor, and Veloz.

Value

₹16,374 Cr

Torrent Pharmaceuticals Annual General Meeting

Torrent Pharmaceuticals scheduled its 53rd Annual General Meeting for June 23, 2026. Key agenda items include adopting FY26 financial statements, confirming dividends, and re-appointing Director Samir Mehta.

Torrent Pharmaceuticals Other Announcement

Torrent Pharmaceuticals submitted its Business Responsibility and Sustainability Report for FY 2025-26. This routine filing outlines the company's ESG performance and strategic sustainability initiatives.

Torrent Pharmaceuticals Annual Report

Torrent Pharmaceuticals submitted its Integrated Annual Report for FY 2025-26. The document includes the 53rd AGM notice and details regarding remote e-voting procedures.

Torrent Pharmaceuticals Earnings Call: Key Takeaways

Torrent Pharma Q4 FY26 revenue rose 42% to ₹4,197cr, driven by JB Pharma consolidation. Combined EBITDA margin stood at 32.3%, with focus on Semaglutide ramp-up in India and synergy execution.

Torrent Pharmaceuticals Other Announcement

Torrent Pharmaceuticals submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms full adherence to SEBI listing regulations and statutory provisions.

Torrent Pharmaceuticals Earnings Call: Key Takeaways

Torrent Pharma delivered strong Q4 growth led by India and Brazil, while successfully integrating Curatio and JB Pharma assets.

Torrent Pharmaceuticals Fund Raise of ₹10,990 Cr

Torrent Pharmaceuticals confirmed full utilization of ₹10,990 Crore raised via NCDs for acquiring J.B. Chemicals shares. No deviations occurred during the quarter ended March 2026.

Value

₹10,990 Cr

Torrent Pharmaceuticals Debt & Borrowing: ₹11,156 Cr

Torrent Pharmaceuticals Limited filed its security cover certificate for outstanding NCDs totaling ₹11,156.14 Crore. The filing confirms adequate asset coverage as of March 2026.

Value

₹11,156 Cr

Torrent Pharmaceuticals Dividend

Torrent Pharmaceuticals fixed May 29, 2026, as the record date for final dividend eligibility. Shareholders must hold stock by this date to receive the payment.

Torrent Pharmaceuticals Q4 FY26 Results: Net Profit ₹364 Cr, Down 26.9% YoY

Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,197 Cr (+41.8% YoY) and net profit of ₹364 Cr (-26.9% YoY) for Q4 FY26.

Key figure

Net profit ₹364 Cr · -26.9% YoY

Torrent Pharmaceuticals Financial Results

Torrent Pharma reported annual consolidated revenues of ₹13,980 Crore. The board recommended a ₹9 final dividend and approved a ₹5,000 Crore enabling fundraise via QIP.

Value

₹5,000 Cr

Torrent Pharmaceuticals Board Meeting Date

Torrent Pharmaceuticals scheduled a May 22, 2026, conference call to discuss its quarterly and annual financial results. Investors can join via provided dial-in numbers.

Torrent Pharmaceuticals Board Meeting Date

Torrent Pharmaceuticals will hold a board meeting on May 22, 2026. Agenda includes auditing yearly results, final dividend declaration, and proposed fund raising via QIP.

Torrent Pharmaceuticals Board Meeting Date

Torrent Pharmaceuticals scheduled a board meeting on May 22, 2026, to approve annual results and dividends. The board will also consider raising funds through equity.

Torrent Pharmaceuticals Acquisition

Torrent Pharmaceuticals Limited shareholders approved the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with the company in an NCLT-convened meeting on April 28, 2026. The resolution was passed by a requisite majority representing three-fourths in value. The amalgamation marks a significant strategic consolidation for Torrent Pharma.